Regularly eating foods like bacon and sausages may raise the risk of breast cancer, according to researchers.
A review of studies found women who ate high levels of processed meat had a 9 percent increased risk of the cancer compared with those who ate little of it.
The study backs up previous findings of the World Health Organisation, which says processed meats cause cancer.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.